261 related articles for article (PubMed ID: 22509024)
1. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia.
Kang R; Loux T; Tang D; Schapiro NE; Vernon P; Livesey KM; Krasinskas A; Lotze MT; Zeh HJ
Proc Natl Acad Sci U S A; 2012 May; 109(18):7031-6. PubMed ID: 22509024
[TBL] [Abstract][Full Text] [Related]
2. AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway.
Kang R; Tang D; Lotze MT; Zeh HJ
Autophagy; 2012 Jun; 8(6):989-91. PubMed ID: 22722139
[TBL] [Abstract][Full Text] [Related]
3. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
4. The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.
Vernon PJ; Loux TJ; Schapiro NE; Kang R; Muthuswamy R; Kalinski P; Tang D; Lotze MT; Zeh HJ
J Immunol; 2013 Feb; 190(3):1372-9. PubMed ID: 23269246
[TBL] [Abstract][Full Text] [Related]
5. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.
DiNorcia J; Lee MK; Moroziewicz DN; Winner M; Suman P; Bao F; Remotti HE; Zou YS; Yan SF; Qiu W; Su GH; Schmidt AM; Allendorf JD
J Gastrointest Surg; 2012 Jan; 16(1):104-12; discussion 112. PubMed ID: 22052106
[TBL] [Abstract][Full Text] [Related]
6. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.
Kang R; Tang D; Schapiro NE; Livesey KM; Farkas A; Loughran P; Bierhaus A; Lotze MT; Zeh HJ
Cell Death Differ; 2010 Apr; 17(4):666-76. PubMed ID: 19834494
[TBL] [Abstract][Full Text] [Related]
7. The advanced glycation end-product N
Menini S; Iacobini C; de Latouliere L; Manni I; Ionta V; Blasetti Fantauzzi C; Pesce C; Cappello P; Novelli F; Piaggio G; Pugliese G
J Pathol; 2018 Jun; 245(2):197-208. PubMed ID: 29533466
[TBL] [Abstract][Full Text] [Related]
8. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
9. Opposing roles of RAGE and Myd88 signaling in extensive liver resection.
Zeng S; Zhang QY; Huang J; Vedantham S; Rosario R; Ananthakrishnan R; Yan SF; Ramasamy R; DeMatteo RP; Emond JC; Friedman RA; Schmidt AM
FASEB J; 2012 Feb; 26(2):882-93. PubMed ID: 22075646
[TBL] [Abstract][Full Text] [Related]
10. The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury.
Kang R; Tang D; Livesey KM; Schapiro NE; Lotze MT; Zeh HJ
Antioxid Redox Signal; 2011 Oct; 15(8):2175-84. PubMed ID: 21126167
[TBL] [Abstract][Full Text] [Related]
11. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
12. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
[TBL] [Abstract][Full Text] [Related]
13. RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer.
Azizan N; Suter MA; Liu Y; Logsdon CD
Biochem Biophys Res Commun; 2017 Nov; 493(1):592-597. PubMed ID: 28867179
[TBL] [Abstract][Full Text] [Related]
14. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation.
Mills LD; Zhang Y; Marler RJ; Herreros-Villanueva M; Zhang L; Almada LL; Couch F; Wetmore C; Pasca di Magliano M; Fernandez-Zapico ME
J Biol Chem; 2013 Apr; 288(17):11786-94. PubMed ID: 23482563
[TBL] [Abstract][Full Text] [Related]
15. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics.
Kang R; Tang D; Schapiro NE; Loux T; Livesey KM; Billiar TR; Wang H; Van Houten B; Lotze MT; Zeh HJ
Oncogene; 2014 Jan; 33(5):567-77. PubMed ID: 23318458
[TBL] [Abstract][Full Text] [Related]
16. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells.
Huang JS; Guh JY; Chen HC; Hung WC; Lai YH; Chuang LY
J Cell Biochem; 2001; 81(1):102-13. PubMed ID: 11180401
[TBL] [Abstract][Full Text] [Related]
17. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D.
Baumgart S; Chen NM; Siveke JT; König A; Zhang JS; Singh SK; Wolf E; Bartkuhn M; Esposito I; Heßmann E; Reinecke J; Nikorowitsch J; Brunner M; Singh G; Fernandez-Zapico ME; Smyrk T; Bamlet WR; Eilers M; Neesse A; Gress TM; Billadeau DD; Tuveson D; Urrutia R; Ellenrieder V
Cancer Discov; 2014 Jun; 4(6):688-701. PubMed ID: 24694735
[TBL] [Abstract][Full Text] [Related]
18. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
19. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.
Sato K; Hikita H; Myojin Y; Fukumoto K; Murai K; Sakane S; Tamura T; Yamai T; Nozaki Y; Yoshioka T; Kodama T; Shigekawa M; Sakamori R; Tatsumi T; Takehara T
PLoS One; 2020; 15(7):e0235573. PubMed ID: 32609742
[TBL] [Abstract][Full Text] [Related]
20. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
